Skip to main content

Table 1 Subject characteristics

From: Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

  Without NAFLD With NAFLD
Variables Total Non-CAD CAD Total Non-CAD CAD
N = 183 N = 47 N = 136 N = 70 N = 27 N = 43
Sex(Male/Female) 121/62 23/24 98/38 43/27 16/11 27/16
Age, years 67.2 ± 10.0 64.6 ± 9.9 68.2 ± 9.9* 63.9 ± 9.9# 61.3 ± 7.7 65.5 ± 10.9
Body mass index, kg/m2 23.9 ± 3.1 24.0 ± 3.5 23.9 ± 2.9 26.5 ± 3.7## 26.5 ± 4.9 26.5 ± 2.8
Waist circumference, cm 88.4 ± 9.3 86.7 ± 9.8 88.9 ± 9.0 95.4 ± 9.3## 96.6 ± 11.7 94.7 ± 7.6
Systolic blood pressure, mmHg 130.0 130.0 130.0 140.0 140.0 140.0
(120.0-148.0) (119.0-150.0) (120.0-147.8) (128.8-151.5)# (120.0-150.0) (130.0-153.0)
Diastolic blood pressure, mmHg 80.0 80.0 80.0 80.0 80.0 80.0
  (70.0-80.0) (70.0-85.0) (70.0-80.0) (71.8-90.0)## (70.0-85.0) (72.0-90.0)
Fasting plasma glucose, mmol/L 5.3(4.9-6.1) 5.3(5.0-5.9) 5.3(4.9-6.1) 5.8(5.2-7.2)## 5.6(5.1-6.6) 5.9(5.4-7.7)
2 h postprandial glucose, mmol/L 7.9(6.4-10.7) 7.5(6.1-9.3) 8.0(6.5-11.5)* 10.4(8.2-12.9)## 9.7(7.9-12.9) 11.3(8.2-12.9)
HbA1c,% 6.1(5.7-6.5) 5.9(5.6-6.3) 6.2(5.8-6.6) 6.5(5.9-7.6)## 6.3(5.7-7.1) 6.6(6.2-7.9)
HOMA-IR 3.8(2.4-5.3) 3.7(2.4-5.4) 3.9(2.4-5.3) 6.0(3.7-7.2)## 5.9(3.7-6.4) 6.6(3.7-9.2)
Total cholesterol, mmol/L 4.3 ± 1.0 4.6 ± 1.1 4.2 ± 1.0* 4.7 ± 1.3# 4.5 ± 1.4 4.8 ± 1.2
Triglyceride, mmol/L 1.4(1.0-1.9) 1.4(0.9-2.0) 1.4(1.0-1.8) 2.2(1.4-3.1)## 1.7(1.3-2.4) 2.6(1.6-3.7)*
HDL-c, mmol/L 1.1 ± 0.3 1.2 ± 0.3 1.1 ± 0.3* 1.0 ± 0.3## 1.0 ± 0.3 1.0 ± 0.3
LDL-c, mmol/L 2.9 ± 1.0 3.0 ± 0.9 2.9 ± 1.0 3.1 ± 1.0 3.1 ± 1.0 3.2 ± 1.0
C-reactive protein, mg/L 1.2(0.5-3.1) 1.0(0.4-3.0) 1.2(0.5-3.3) 2.3(1.0-6.9)## 1.6(0.7-6.3) 2.5(1.1-7.6)
FGF21, pg/mL 273.3 256.1 277.8 388.0 321.5 415.5
(164.9-383.7) (150.6-351.9) (171.1-406.6)* (253.0-655.4)## (239.1-497.6) (258.0-693.7)*
Smoker n (%) 82(44.8) 16(34.0) 66(48.5) 31(44.3) 12(44.4) 19(44.2)
Metabolic syndrome and its components
  Abdominal obesity n (%) 93(50.8) 22(46.8) 71(52.2) 55(78.6)## 21(77.8) 34(79.1)
  Hypertriglyceridemia n (%) 87(47.5) 20(42.6) 67(49.3) 50(71.4)## 14(51.9) 36(83.7)**
  Low HDL-c n (%) 73(39.9) 15(31.9) 58(42.6) 41(58.6)# 14(51.9) 27(62.8)
  Hypertension n (%) 160(87.4) 41(87.2) 119(87.5) 63(90.0) 23(85.2) 40(93.0)
  Hyperglycemia n (%) 105(57.4) 25(53.2) 80(58.8) 56(80.0)## 21(77.8) 35(81.4)
  Metabolic syndrome n (%) 105(57.4) 24(51.1) 81(59.6) 63(90.0)## 23(85.2) 40(93.0)
Dyslipidemia n (%) 142(77.6) 34(72.3) 108(79.4) 68(97.1)## 25(92.6) 43(100.0)
  1. Data were expressed as mean ± SD or median (interquartile range). For both the non-NAFLD and NAFLD groups: *P < 0.05 CAD vs. non-CAD; **P < 0.01 CAD vs. non-CAD. For the total subjects with and without NAFLD: #P < 0.05 NAFLD vs. non-NAFLD; ##P < 0.01 NAFLD vs. non-NAFLD.